Tirzepatide is a medication developed to target two important hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These hormones belong to the incretin system, which helps regulate blood glucose levels after food consumption. Tirzepatide acts as a dual GIP and GLP-1 receptor agonist, influencing several metabolic processes.
Research has focused on how this dual activity affects insulin secretion, glucagon production, appetite, and digestion. Its effects are particularly relevant to individuals with type 2 diabetes and obesity.
GIP receptor activation: Supports glucose-dependent insulin secretion and contributes to metabolic regulation.
GLP-1 receptor activation: Helps stimulate insulin release when blood glucose levels are elevated.
Blood glucose regulation: Supports the body's ability to manage glucose levels after meals.
Appetite regulation: Influences appetite-related signals and food intake.
Gastric emptying: Slows the movement of food from the stomach into the small intestine, particularly during initial treatment.
Clinical research has investigated tirzepatide's effects on glycemic control, body weight, insulin sensitivity, and other metabolic indicators. Studies involving people with type 2 diabetes have reported improvements in blood glucose measurements, including HbA1c levels. Research has also examined its effects on body weight and related metabolic risk factors.
The SURPASS clinical trial programme evaluated tirzepatide in people with type 2 diabetes, while the SURMOUNT programme investigated its effects on weight management in people with obesity or overweight under specified clinical conditions.
Glycemic control: Clinical trials have demonstrated reductions in HbA1c levels among participants with type 2 diabetes.
Body weight changes: Research has reported significant weight reductions in studied populations.
Insulin response: Tirzepatide supports glucose-dependent insulin secretion.
Metabolic indicators: Studies have examined changes in waist circumference and other metabolic measurements.
Safety considerations: Common adverse effects include nausea, diarrhoea, vomiting, constipation, and decreased appetite.
Research continues to examine the long-term metabolic effects of tirzepatide, differences in individual responses, and its potential effects on cardiovascular and other health outcomes. Treatment suitability, dosage, and monitoring require assessment by qualified healthcare professionals.